Huntington's Disease Treatment Market Size

Huntington's Disease Treatment Market Analysis

Huntington's disease treatment market is projected to register a CAGR of 21% during the forecast period.

COVID-19 had a significant impact on the growth of the market. According to the European Huntington Association data updated in May 2021, patients with Huntington's disease (HD) do not necessarily have a higher risk of getting COVID-19 due to the disease itself. However, patients with symptomatic Huntington's disease may have a higher chance of getting pneumonia since they are more likely to be bedridden and malnourished. HD patients could be more susceptible to symptoms if exposed to COVID-19 and have more major diseases. As a result, there was a strong demand for effective treatment of the target disease during the pandemic since people with Huntington's disease were at risk of contracting COVID-19 infection. The COVID-19 pandemic has subsided globally. Thus, the market is anticipated to experience stagnant growth during the forecast period.

Factors such as the global prevalence of Huntington's disease are expected to drive the target market's growth. As per the article published in the Journal of Neuroepidemiology in November 2021, the prevalence of Huntington's disease was around 10 cases per 100,000 people annually, with a higher prevalence in North America, Northwestern Europe, the Middle East, and Australia. In the regions mentioned above, the estimated range of Huntington's disease is between 5.96 and 13.70 cases per 100,000 people. As per the same source, in Asia, the prevalence is estimated to be 0.41-0.70 cases per 100,000 people annually. As Huntington's disease becomes more common, the need for effective treatments is anticipated to increase, fueling the market's growth throughout the forecast period.

Increasing R&D activities and product development are also expected to contribute to the market's growth over the forecast period. For instance, in April 2021, Voyager Therapeutics Inc. received the US FDA clearance for an IND application for its VY-HTT, a gene therapy candidate designed to treat Huntington's disease. The therapy is designed to reduce the expression of the huntingtin gene to alter the disease progression further. Similarly, in December 2021, uniQure NV presented clinical outcomes for the first four patients enrolled in the lower-dose cohort of its ongoing Phase I/II clinical trial of AMT-130. AMT-130 is a gene therapy program designed to treat Huntington's disease.

However, the high cost of developing effective treatment is expected to hamper the market's growth over the forecast period.